Results 121 to 130 of about 51,155 (263)

Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report. [PDF]

Am J Case Rep
Sanji Y, Matsushita I, Takahashi E, Fukui M, Kitajima H, Kaneuji A.   +5 more
europepmc   +1 more source

Dietary Habits and Atopic Dermatitis Significantly Influence the Fecal Microbiome

Allergy, EarlyView.
Atopic dermatitis, dietary habits, sex, and BMI significantly influenced the fecal microbiome composition. On the species level, Faecalibacterium taiwanense was more abundant in atopic dermatitis, and Vescimonas sp000435555 was more abundant in the control population. On the genus level, CAG‐302 (NCBI: Clostridium) was more abundant in controls.
Danielle Fehr, Nicole Flack, Gloria Masenga, Nelson Mosha, Nick Li, Anna White, George Semango, Meike Distler, Claudia Lang, Felix Grimm, Michael Scharl, Daudi Mavura, John Elisante Masenga, Peter Schmid‐Grendelmeier, Marie‐Charlotte Brüggen   +14 more
wiley   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Acute retinal necrosis during the systemic use of Janus kinase inhibitor. [PDF]

Int J Retina Vitreous
Watanabe D, Namba K, Hase K, Suzuki K, Ogino Y, Saito M, Iwata D, Mizuuchi K, Hiraoka M, Narita M, Kitaichi N, Kitaya N, Ishida S.   +12 more
europepmc   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Short-term omalizumab as a potential rescue therapy for alopecia areata flares during Janus kinase inhibitor maintenance. [PDF]

JAAD Int
Wang Q, Cheng K, Lin JM, Tao K, Xu M, Zhang X, Tang S, Ni C, Wu W, Lin J.   +9 more
europepmc   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor-experienced patients with myelofibrosis. [PDF]

J Patient Rep Outcomes
Cutts K, Cardellino A, Zhang S, Phiri K, Gelhorn H.   +4 more
europepmc   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source